Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

Frail Older Patients With AF May Fare Better Switching to DOAC

News Daily News

Frail Older Patients With AF May Fare Better Switching to DOAC

August 05, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

News Conference News HRS 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

April 29, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

USPSTF: Data Around Screening for AF in Asymptomatic Adults Still Lacking

News Daily News

USPSTF: Data Around Screening for AF in Asymptomatic Adults Still Lacking

January 25, 2022

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

Trials Suggest Need for Prolonged AF Monitoring in More Stroke Patients

News Daily News

Trials Suggest Need for Prolonged AF Monitoring in More Stroke Patients

June 04, 2021

Experts Update Antithrombotic Advice in AF Patients Undergoing PCI

News Daily News

Experts Update Antithrombotic Advice in AF Patients Undergoing PCI

February 09, 2021

News Conference News ESC 2020

Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4

August 29, 2020

New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose

News Daily News

New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose

March 12, 2020

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Remission, Not Cure: No Weaning Off Meds for Dilated Cardiomyopathy Patients, Says TRED-HF

News Conference News AHA 2018

Remission, Not Cure: No Weaning Off Meds for Dilated Cardiomyopathy Patients, Says TRED-HF

November 11, 2018

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

News Daily News

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

August 14, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.